- Home
- VRDN vs KNSA Comparison
VRDN vs KNSA Comparison
Compare VRDN & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRDN
- KNSA
- Stock Information
- Founded
- VRDN 2006
- KNSA 2015
- Country
- VRDN United States
- KNSA United Kingdom
- Employees
- VRDN N/A
- KNSA N/A
- Industry
- VRDN Medical Specialities
- KNSA Biotechnology: Pharmaceutical Preparations
- Sector
- VRDN Health Care
- KNSA Health Care
- Exchange
- VRDN Nasdaq
- KNSA Nasdaq
- Market Cap
- VRDN 1.6B
- KNSA 1.5B
- IPO Year
- VRDN N/A
- KNSA 2018
- Fundamental
- Price
- VRDN $13.13
- KNSA $20.21
- Analyst Decision
- VRDN Buy
- KNSA Strong Buy
- Analyst Count
- VRDN 12
- KNSA 6
- Target Price
- VRDN $36.44
- KNSA $37.17
- AVG Volume (30 Days)
- VRDN 1.2M
- KNSA 638.0K
- Earning Date
- VRDN 05-07-2025
- KNSA 04-29-2025
- Dividend Yield
- VRDN N/A
- KNSA N/A
- EPS Growth
- VRDN N/A
- KNSA N/A
- EPS
- VRDN N/A
- KNSA N/A
- Revenue
- VRDN $302,000.00
- KNSA $423,239,000.00
- Revenue This Year
- VRDN N/A
- KNSA $37.21
- Revenue Next Year
- VRDN $20,553.29
- KNSA $2.58
- P/E Ratio
- VRDN N/A
- KNSA N/A
- Revenue Growth
- VRDN N/A
- KNSA 56.60
- 52 Week Low
- VRDN $9.90
- KNSA $16.56
- 52 Week High
- VRDN $27.20
- KNSA $28.15
- Technical
- Relative Strength Index (RSI)
- VRDN 46.75
- KNSA 44.56
- Support Level
- VRDN $9.90
- KNSA $18.26
- Resistance Level
- VRDN $14.22
- KNSA $21.24
- Average True Range (ATR)
- VRDN 1.17
- KNSA 1.12
- MACD
- VRDN 0.18
- KNSA -0.12
- Stochastic Oscillator
- VRDN 74.77
- KNSA 44.43
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.